Aktis Oncology, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Aktis Oncology, Inc. (AKTS), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are AKTS insiders buying or selling?
In the last 12 months, Aktis Oncology, Inc. insiders reported 6 open-market purchases ($114.3M) and 5 sales ($3.2M) — net buying of $111.1M. Since January 2026, Trabud has recorded 11 Form 4 filings for AKTS: 6 buys ($114.3M) and 5 sells ($3.2M).
Source: SEC EDGAR Form 4
What stands out
- The largest open-market purchase in the last 12 months was $40.0M by EcoR1 Capital, LLC (Director) on Jan 13, 2026. SEC ↗
- The most recent open-market purchase was reported on Jan 14, 2026 (9 months ago).
Key Statistics (January 2026 – Sep 24, 2026)
Total Form 4 filings
11
SEC EDGAR
Insider filers
9
Insider buys (6)
$114.3M
Insider sells (5)
$3.2M
Insider sentiment
Net buyingNet insider flow of $111.1M in net buying since January 2026, and $111.1M in net buying over the last 12 months.
Recent AKTS insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 24, 2026 | Akos Czibere | Chief Medical Officer | Sale | 12.5K | $20.69 | $258.6K | SEC ↗ |
| Jul 22, 2026 | Ken Herrmann | Director | Sale | 4.9K | $24.56 | $119.3K | SEC ↗ |
| Jul 20, 2026 | Ken Herrmann | Director | Sale | 3.1K | $25.21 | $77.3K | SEC ↗ |
| Jul 10, 2026 | Shulamit Ron-Bigger | Chief Operating Officer | Sale | 50.0K | $27.75 | $1.4M | SEC ↗ |
| Jul 10, 2026 | Akos Czibere | Chief Medical Officer | Sale | 50.0K | $27.77 | $1.4M | SEC ↗ |
| Jan 14, 2026 | Todd Foley | Director, 10% Owner | Purchase | 232.9K | $18.00 | $4.2M | SEC ↗ |
| Jan 14, 2026 | Luke Evnin | 10% Owner | Purchase | 1.1M | $18.00 | $20.0M | SEC ↗ |
| Jan 14, 2026 | Ansbert Gadicke | 10% Owner | Purchase | 1.1M | $18.00 | $20.0M | SEC ↗ |
| Jan 13, 2026 | EcoR1 Capital, LLC | Director | Purchase | 2.2M | $18.00 | $40.0M | SEC ↗ |
| Jan 12, 2026 | Vida Ventures II, LLC | 10% Owner | Purchase | 835.0K | $18.00 | $15.0M | SEC ↗ |
| Jan 12, 2026 | Helen Susan Kim | Director, 10% Owner | Purchase | 835.0K | $18.00 | $15.0M | SEC ↗ |
Showing the 11 most recent of 11 Form 4 filings for Aktis Oncology, Inc..
Most active AKTS insiders
- Akos Czibere2 filings
- Ken Herrmann2 filings
- Ansbert Gadicke1 filing
- EcoR1 Capital, LLC1 filing
- Helen Susan Kim1 filing
Ask anything about AKTS insider activity
Use Trabud's AI agent to query Aktis Oncology, Inc.'s Form 4 history in plain English — "Show me AKTS CEO purchases this year" or compare it against any other ticker.
Open the AI agentAKTS insider trading FAQ
Are Aktis Oncology, Inc. insiders buying or selling?
In the last 12 months, Aktis Oncology, Inc. insiders reported 6 open-market purchases ($114.3M) and 5 sales ($3.2M) — net buying of $111.1M. Since January 2026, Trabud has recorded 11 Form 4 filings for AKTS: 6 buys ($114.3M) and 5 sells ($3.2M). Over the full record that is net buying of $111.1M.
How many insiders trade AKTS stock?
9 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Aktis Oncology, Inc.. The most recent filing was accepted on Sep 24, 2026.
Where does Trabud get AKTS insider trading data?
All AKTS insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.